Surgical Site Infection Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy at Initial Closure

Surgery Clinical Trial

Official title:

Surgical Site Infection (SSI) Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy (NPWT) at Initial Closure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01924884
• Other study ID #: IRB00155110
• Secondary ID: NA_00052186
• Status: Completed
• Start date: July 2013
• Est. completion date: October 2019

Study information

• Verified date: January 2020
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this study is to present a large single-institution experience reporting surgical site infection rates in patients who have undergone intra-abdominal surgery followed by wound closure with Negative Pressure Wound Therapy. A retrospective review of patients' charts will be conducted to analyze surgical site infection rates between wound closure with and without Negative Pressure Wound Therapy (NPWT). American College of Surgeons National Quality Improvement Program data from previous standard of care (primary closure after colorectal surgery) will be used for comparison with newly adopted standard of care treatment regimen (wound closure with NPWT).

Data on patients who underwent intra-abdominal surgery will be retrospectively collected and a database will be created. These individuals will be identified through medical records and recontacted by mail and/or phone to collect study data.

Finally, patients newly referred to the Principal Investigator for intra-abdominal surgery will be enrolled in the database. After giving informed consent, data on surgical site infection rates and outcomes will be collected. Longitudinal outcomes will be assessed at 30 days, 6 months, and 12 months post-operatively. These patients' outcomes will be compared to a group of patients treated by the Principal Investigator who also underwent intra-abdominal surgery without Negative Pressure Wound Therapy. We hypothesize that fewer patients treated with negative pressure wound therapy following intra-abdominal surgery will develop surgical site infections than patients who had intra-abdominal surgery but were not treated with Negative Pressure Wound Therapy.

Description:

Duration of individual study participation will last approximately one year for prospectively enrolled participants. Data collection for retrospectively enrolled patients will span approximately 12 months.

Study data will not be collected on subjects until eligibility is confirmed and the patient is assigned a study number.

All information will be collected in a secure study-specific electronic registry database. The data will be reviewed for completeness and accuracy by the Principal Investigator. This is an observational registry which does not include an investigatory agent and poses minimal risk to the participants. Thus, the monitoring will be done by the study personnel - an independent board is not necessary.

This study will use the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4. Information about all adverse events, whether volunteered by the subject, discovered by the investigator, or detected through physical examination, laboratory test, or other means, will be collected, recorded, and followed as appropriate. All adverse events experienced by participants will be collected and reported from the time of consent until the Day 30 follow-up appointment, as appropriate. Thereafter, only adverse events of interest (i.e., death, additional hospitalization, surgical site infection, surgical site occurrence) will be recorded. Participants who have an ongoing adverse event related to the study procedures may continue to be periodically contacted by a member of the study staff until the event has resolved or determine to be irreversible by the principal investigator. All adverse events and serious adverse events will be reported to the Johns Hopkins Medicine Institutional Review Board.

To generate a large data set that may be used to answer various research questions, enrollment will continue for at least 10 years, generating an estimated patient sample size of n=1200. The study team anticipates enrolling 100-150 patients in the study registry per year over 10 years.

Simple descriptive statistics will be used to determine the rate of SSIs in colorectal surgery patients. This rate will be compared with the SSI rate published in literature to determine if implementation of negative pressure wound therapy wound closure following colorectal surgery decreases the rate of SSIs in colorectal surgery patients. A hypothesis test will be used to determine if there is a difference before and after adoption of negative pressure wound therapy wound closure. Enrollment of subjects over several years will enable further analyses with the possibility of stratification according to different patient characteristics.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: October 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Greater than or equal to 18 years of age

• Undergoing intra-abdominal surgery at Johns Hopkins Hospital by Dr. Frederic Eckhauser

Exclusion Criteria:

• Less than 18 years of age

• Pregnant females

Related Conditions & MeSH terms

• Abdominal Injuries
• Communicable Diseases
• Infection
• Surgery
• Surgical Wound
• Surgical Wound Infection
• Wound Infection
• Wound; Abdomen, Abdominal Wall
• Wounds and Injuries

Locations

Country	Name	City	State
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	Kinetic Concepts, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quantifying post-operative morbidity and mortality rates among patients undergoing enterocutaneous fistula and ventral hernia repair with or without negative pressure wound therapy.	Objective: To determine morbidity and mortality secondary to enterocutaneous fistula and ventral hernia repair in this patient population.	Up to one year
Primary	Surgical site infection (per the 1999 Guideline for Prevention of Surgical Site Infection from the Hospital Infections Program at the National Center for Infectious Diseases, Centers for Disease Control and Prevention).	Comparing surgical site infection (per the 1999 Guideline for Prevention of Surgical Site Infection from the Hospital Infections Program at the National Center for Infectious Diseases) rates between patients treated with and without negative pressure wound therapy.; Objective: To determine if a newly adopted standard of care [negative pressure wound therapy (NPWT)] for clean, clean-contaminated, and contaminated wounds will lead to decreased rates of post-operative surgical site infection.	Up to one year
Secondary	Surgical site occurrence (per the 2010 Ventral Hernia Working Group's classification and the modified hernia grading scale by Kanters et al.; 2012).	Comparing surgical site occurrence (per the 2010 Ventral Hernia Working Group's classification and the modified hernia grading scale by Kanters et al.; 2012) rates between patients treated with and without negative pressure wound therapy.; Objective: To determine if a newly adopted standard of care [negative pressure wound therapy (NPWT)] for clean, clean-contaminated, and contaminated wounds will lead to decreased rates of post-operative surgical site occurrence.	Up to one year
Secondary	Quantifying post-operative morbidity and mortality rates among patients undergoing bowel surgery with or without negative pressure wound therapy.	Objective: To determine if a newly adopted standard of care [negative pressure wound therapy (NPWT)] for clean, clean-contaminated, and contaminated wounds will improve outcomes of bowel surgery patients.	Up to one year